perspective, using data from a recently published Bayesian network meta-analysis. Methods: Analysis was conducted through a threestate Markov model and used data on the progression of disease with treatment from the gemcitabine arms of randomized controlled trials combined with estimates from the network meta-analysis for the newer regimens. Estimates of health care costs were obtained from local providers, and utilities were derived from the literature. The model estimates the effect of treatment regimens on costs and quality-adjusted life-years (QALYs) discounted at 5% per annum. Results: At a willingness-to-pay (WTP) threshold of greater than $30,666 per QALY, FOLFIRINOX would be the most optimal regimen. For a WTP threshold of $50,000 per QALY, the probability that FOLFIRINOX would be optimal was 57.8%. There was no price reduction for nab-paclitaxel when GnP was optimal. Conclusions: From a Canadian public health payer's perspective at the present time and drug prices, FOLFIRINOX is the optimal regimen on the basis of the cost-effectiveness criterion. GnP is not cost-effective regardless of the WTP threshold.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related deaths in Canada, with a median overall survival (OS) of 3 to 5 months without treatment for those with metastatic disease [1] . With fewer than 5% of patients surviving 5 years, prognosis remains poor as mortality rates in pancreatic cancer closely reflect the incidence rates [2] . The availability of new drugs and combinations, however, has significantly improved the outcome of patients with metastatic pancreatic cancer (MPC), increasing the median OS to 8 to 12 months.
For over a decade, gemcitabine (G) alone has been considered the standard of care for the treatment of MPC because of the promising results of a landmark phase III randomized controlled trial (RCT) that compared G with 5-fluorouracil [3] . Since the publication of this study, many cytotoxic and targeted agents have been tried in combination with G [4] [5] [6] [7] [8] [9] . Among these trials, only three have shown statistically significant improvements in median OS and survival rates compared with G monotherapy [3, 4, 10] .
Consequently, G þ erlotinib (GE), FOLFIRINOX, and G þ nabpaclitaxel (GnP) have emerged as alternatives to G monotherapy for the treatment of chemotherapy-naive patients with MPC.
Despite the success of these treatments in improving the life expectancy of patients with MPC, they are also associated with greater side effects and higher costs than G monotherapy. Furthermore, at present there is a lack of direct pairwise comparisons between these combination therapies. Thus, in a previous study we performed a Bayesian network meta-analysis (NMA) to determine the most effective treatment for advanced pancreatic cancer, taking into account the efficacy and safety profiles of each regimen [11] . A Bayesian NMA, an extension of the traditional pairwise meta-analysis, is used to simultaneously compare multiple interventions even in the absence of direct evidence (i.e., RCTs). In our previous study, we found that FOLFIRINOX had the highest probability of being the best regimen (83%), followed by GnP (11%), on the basis of OS data [11] . In addition, both these regimens had no significant differences in toxicities and the OS hazard ratio for FOLFIRINOX versus GnP was 0.79 (range 0.50-1.24) [11] .
For optimal resource allocation, decision makers require both efficacy and relative cost data to evaluate trade-offs when choosing between multiple interventions. Because many of the therapies included in this analysis have not been directly compared in head-to-head RCTs, our previously conducted NMA synthesized effectiveness evidence from all sources (direct and indirect) for use in this cost-effectiveness model. The objective of this study was to assess the incremental cost-effectiveness of the alternative treatment options for advanced pancreatic cancer. This was achieved through the development of a decision analytic model populated with data from our previously conducted Bayesian NMA.
Methods

Analytical Framework
We used decision analytic modeling to simulate the lifetime outcomes with different chemotherapeutic regimens in the treatment of advanced pancreatic cancer. A time horizon of 10 years, which effectively equates to a lifetime horizon given the extremely poor prognosis of patients with advanced pancreatic cancer, was adopted for this analysis [2] . Outcomes were assessed in terms of cost and quality-adjusted life-years (QALYs), with cost-effectiveness assessed through estimation of incremental cost-effectiveness ratios (ICERs). Optimal treatment options can be inferred through the conduct of a sequential costeffectiveness analysis. For this study, the Canadian public health payer's perspective was adopted [12] .
Patient Population
Analysis was conducted for a patient cohort representing patients receiving first-line treatment for advanced pancreatic cancer or adenocarcinoma. In the base-case analysis, the mean age of the cohort was 63 years, with 60% of the cohort being male.
Comparators
The predefined basis of this economic evaluation was to conduct a cost-effectiveness analysis on the basis of the regimens included in our recently published NMA [11] . Therefore, the comparators included were G alone (the previous standard
, and FOLFIRINOX. G þ tegafur/gimeracil/ oteracil (S-1) was excluded in this economic evaluation because S-1 is not approved and marketed in Canada.
Model
We developed a Markov model to estimate the costs and QALYs associated with therapies for advanced pancreatic cancer. The model consisted of three states relating to disease progression: preprogression, postprogression, and death (Fig. 1) . During the preprogression state, however, patients can experience side effects from therapy. This can be characterized as having multiple preprogression states (substates)-one relating to the absence of side effects and others relating to the presence of neuropathy, fatigue, diarrhea, febrile neutropenia, and/or rash.
The cycle length was assumed to be 4 weeks. Side effects were assumed to commence at the onset of treatment-within the first cycle-with patients remaining in the relevant health state for a period of time on the basis of the duration of the side effect.
Transition Probabilities
On the basis of the Markov model, patients in the preprogression state can either transition to the postprogression state or death or remain in the preprogression state. Patients in the postprogression state can transition to death or remain in the postprogression state-patients cannot return to the preprogression state. The detailed methods for determining all transition probabilities are provided in Appendix A in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2016.11.002.
Briefly, for estimation of the transition from preprogression to postprogression or death, we derived data from a published clinical trial based on the methods of Guyot et al. [13] and Van Hoff et al. [14] . The trial was chosen on the basis of there being sufficient data to derive individual patient data as well as its clinical relevance to the Canadian population. The timedependent probability of transition from the preprogression state was derived through appropriate parametric survival analysis [15] . The chosen model, a Weibull distribution, was judged adequate in that it had both the best fit and a strong clinical face validity. We then applied data from the NMA to estimate transitions for all therapies. To incorporate the impact of side effects into this analysis, pooled estimates of the incidence of each side effect were derived from available trials of G and then odds ratios were applied from the NMA to estimate incidence for other therapies. For sensitivity analysis, this approach was repeated using data from five alternative clinical trials [10, [15] [16] [17] [18] .
Costs
Costs for individual therapies were derived from present funding arrangements under the New Drug Funding Program of the Ontario Public Drug Plan, which covers hospital-administered drugs. For drugs not covered under this program, present costs from the Princess Margaret Hospital in Toronto were applied. Costs were based on target dosage of the drug therapies (mg/m 2 / cycle), dose intensity in clinical practice, wastage, administration costs, medical management costs, pharmacy costs, and concomitant medications. The starting dose of the regimens used in this analysis are specified in Appendix B. Analysis assumed an average body surface area of 1.8 m
2
. Although drug acquisition costs were considered fixed, both body surface area and dose intensity were considered uncertain. To model a reasonable 
degree of uncertainty around the dose intensities, an SD of approximately half the difference between the published mean and 100% dose intensity was assumed.
Both costs for patients in the postprogression state and the costs of individual side effects were derived from previous Canadian cost-effectiveness analyses or from Ontario-based cost estimates using administrative data [19] [20] [21] . Sensitivity analysis assessed the impact of assuming an incremental management cost of $200 per month in the preprogression state. All costs are presented in 2016 Canadian dollars.
Utilities
Utility values for patients in the preprogression (0.81) and postprogression (0.73) states were obtained from the analysis of EuroQol data from patients with advanced pancreatic cancer participating in a multicenter, double-blind, randomized trial [22] . Utility decrements associated with side effects were derived from a recent study in which values were obtained from a survey of Canadian oncologists with experience in managing patients with noncolorectal gastrointestinal malignancies [19] .
Analysis
The results are reported as both expected values of outcomes (costs and QALYs) and as ICERs (i.e., the difference in expected costs between two alternatives divided by the difference in expected outcomes). There were more than two alternatives being compared, and so the expected costs and outcomes of the alternatives and the relevant ICERs were calculated sequentially, identifying all comparators that were either dominated (were both costlier and had less QALYs than one of the alternatives) or subject to extended dominance (would not be costeffective regardless of a decision maker's willingness to pay [WTP] for a QALY) [23] .
Deterministic Sensitivity Analyses
One-way sensitivity analyses were conducted to evaluate the sensitivity of the base-case results to changes in assumptions. The following scenarios were considered in our sensitivity analyses. For adverse events, extreme analysis was conducted both excluding adverse events and assuming the duration of 3 months. For form of survival function, analysis was conducted on the basis of the two alternate parametric forms for progression-free survival (exponential and Gompertz). For baseline progression-free survival with G, analysis was conducted on the basis of data from the other clinical trials. For mortality during the preprogression state, analysis was conducted assuming higher mortality on the basis of a relative risk of mortality in the preprogression state of 2. For costs, analysis was conducted assuming an incremental management cost of $200 per month in the preprogression state. Further analysis assessed the degree of price reduction required for the more effective therapies to be considered cost-effective on the basis of commonly cited WTP thresholds of $50,000 and $100,000 per QALY.
Probabilistic Sensitivity Analysis
A probabilistic sensitivity analysis (PSA) was conducted in which each model input parameter was represented by a standard probability distribution (Table 1 ) [24] . Within the PSA, values were randomly drawn from the distribution for each parameter to obtain estimates of the costs and utilities for each treatment strategy. This procedure was repeated 5000 times. The results of the PSA are presented by cost-effectiveness acceptability curves that depict the probability of each treatment strategy being most cost-effective given different threshold values for a QALY (Fig. 2) .
Results
Base-Case Analysis
G is associated with both the least cost and the lowest QALYs, whereas FOLFIRINOX is associated with the greatest QALYs ( Table 2) . FOLFIRINOX was also associated with the highest discounted life expectancy of all the alternatives. The results of the sequential analysis find that GCap, GE, GOx, and GnP were subject to either dominance or extended dominance (see Appendix Figure C1 in Supplemental Materials found at http:// dx.doi.org/10.1016/j.jval.2016.11.002).
Deterministic Sensitivity Analysis
The deterministic sensitivity analysis found the results to be robust in that the original conclusions concerning FOLFIRINOX hold (see Appendix C in Supplemental Materials found at http:// dx.doi.org/10.1016/j.jval.2016.11.002). In all studies based on a decision maker's WTP for a QALY being some value greater than $40,000, FOLFIRINOX is optimal. There was no price reduction associated with nab-paclitaxel that would make GnP optimalthat is, if nab-paclitaxel had a cost of $0, GnP would be subject to extended dominance, in that G, GCis, or GF would be optimal if the WTP for a QALY was less than $30,666 and FOLFIRINOX would be optimal for values greater than $30,666.
Probabilistic Sensitivity Analysis
The probabilistic sensitivity analysis reports similar expected values for costs, QALYs, and incremental ratios than in the base case. G, GCap, GF, GE, GOx, and GnP remain subject to either dominance or extended dominance. At a WTP of $50,000 per QALY, the probability that FOLFIRINOX is optimal is 57.8%, compared with 27.2% for GF, 8.2% for GCis, 5.6% for GCap, 0.7% for GOx, 0.5% for G, and 0% for G and GnP ( Fig. 2 ; see also Appendix Table C2 in Supplemental Materials found at http://dx. doi.org/10.1016/j.jval.2016.11.002). At a WTP of $100,000, the probabilities are 73.8% for FOLFIRINOX, 17.1% for GF, 5.6% for GCap, 3.2% for GCis, 0.5% for GOx, 0.4% for GE, 0.1% for G, and 0% for GnP. Thus, the probability that FOLFIRINOX is optimal is high, inferring a degree of certainty around the result.
In the comparison of FOLFIRINOX with GF, FOLFIRINOX was more effective in 88.1% of replications and had a 65.6% probability of being cost-effective for a threshold of $50,000 per QALY and 79.2% for a threshold of $100,000 per QALY (see Appendix Figure C2 in Supplemental Materials found at http://dx.doi.org/10. 1016/j.jval.2016.11.002). In direct comparison with other treatments, the probability of FOLFIRINOX being cost-effective ranged from 77.8% to 100% for a threshold of $50,000 per QALY and 91% to 100% for a threshold of $100,000 per QALY (see Appendix Table  C3 in Supplemental Materials found at http://dx.doi.org/10.1016/j. jval.2016.11.002).
Discussion
To our knowledge, this is the first study to simultaneously evaluate the cost-effectiveness of these regimens for the treatment of advanced pancreatic cancer. Our analysis found FOLFIR-INOX to be optimal for WTP thresholds greater than $30,666 per QALY. This finding is robust as demonstrated by the results of both the deterministic and probabilistic sensitivity analyses. GOx, 
GE, GCap, and GnP were subject to either dominance or extended dominance.
As a result of the recent introduction of generic oxaliplatin to the Canadian market, a significant price reduction was observed for this drug. Consequently, FOLFIRINOX is the most optimal treatment for advanced pancreatic cancer over a range of WTP thresholds (see Fig. 2 ). Given that FOLFIRINOX was the clinical standard of care before the introduction of GnP, it is important to note that GnP was found to be dominated by FOLFIRINOX in that it was costlier and was associated with lower QALYs.
In the economic evaluation published by Tam et al. [19] , the cost of GE was higher than is reported in this analysis. Tam et al. reported the cost of 150 mg erlotinib, whereas our cost estimation for this drug is based on the dose (100 mg) that more closely reflects the average approximate dose of erlotinib administered in the clinical trial [4] . Thus, the cost of erlotinib (and consequently the cost of GE) is lower in this analysis compared with that of Tam et al. There are limitations of this study that need to be considered. For instance, by taking a public health payer's perspective, our analysis was unable to capture any indirect costs related to the loss of productivity that patients or caregivers may experience because of the toxicities of the treatments. Our analysis also relied on indirect comparisons to obtain relative efficacy data for a number of treatments because of the absence of head-to-head trials. Another limitation was the lack of true individual patient data. The individual patient data reconstruction method used in Note. Lognormal and 1-lognormal distributions are specified by 2.5 and 97.5 percentile, normal distributions by mean and standard error of the mean, beta distributions by alpha and beta, and gamma distributions by shape and scale. Because the duration of treatment cycles vary by regimen, costs were standardized to represent the average cost per 4-wk cycle of the Markov model. Adverse events for grades 3 and 4 were considered for this analysis. GCap, gemcitabine þ capecitabine; GCis, gemcitabine þ cisplatin; GnP, gemcitabine þ nab-paclitaxel; GOx, gemcitabine þ oxaliplatin; OR, odds ratio. Fig. 2 -Cost-effectiveness acceptability curve. This graph depicts the results of the probabilistic sensitivity analysis, showing the probability of each regimen being optimal at different willingness-to-pay thresholds. G, gemcitabine monotherapy; GCap, gemcitabine þ capecitabine; GCis, gemcitabine þ cisplatin; GE, gemcitabine þ erlotinib; GF, gemcitabine þ 5-fluorouracil; GnP, gemcitabine þ nabpaclitaxel; GOx, gemcitabine þ oxaliplatin; QALY, qualityadjusted life-year.
this analysis is a novel application to this area but it does have a number of limitations as indicated by Guyot et al. [13] . To facilitate indirect comparison across the alternative treatment options, we had to make the assumption of proportional hazards with respect to progression-free survival. This is based on the published data, from which the NMA is based, that had made such an assumption. If the proportional hazards assumption does not hold, then analysis comparing multiple treatment strategies based on indirect comparisons would be exceptionally difficult to conduct, thus precluding access to the necessary information required by decision makers. Nevertheless, only two of the studies within the NMA included a discussion of the need to test the proportional hazards assumption and neither of these studies provided details of the results of such tests. We were able to digitize data for six of the included studies, and for each study, the assumption of proportional hazards appeared reasonable. The lack of formal testing of the actual data in all studies is, however, a limitation of the clinical literature and thus a limitation of the economic analysis. We also made the assumption that patients stopped receiving treatment after progression. Because of the poor prognosis of patients with advanced pancreatic cancer, it is clinically realistic to model treatments to progression. Furthermore, variations in clinical practice, differences in drug pricing, and the availability of generic alternatives in different countries limit the generalizability of our findings. For our results to be applicable in other jurisdictions, clinical practice and the relative cost of drugs should ideally be similar to those in Ontario, Canada. Lastly, our findings were based on clinical trial data that may not reflect the real-world population that tends to be older and have more comorbidities. This may lead to greater treatment costs, decreased effectiveness, and less favorable cost-effectiveness estimates than our findings.
Our study adopted utility values for preprogression and postprogression from a previous study using the US algorithm for estimating utility values from the EuroQol five-dimensional questionnaire. Although Canadian data or adoption of the Canadian algorithm would have been preferred, this is unlikely to have affected our results.
Conclusions
FOLFIRINOX was considered the most cost-effective treatment at WTP thresholds greater than $30,666 per QALY. Only at very low WTP thresholds (o$30,666 per QALY), G, GCis, or GF would be considered the most cost-effective regimen for advanced pancreatic cancer. FOLFIRINOX was identified as the most efficacious treatment [11] , the most cost-effective at contemporary Canadian WTP levels, and it continues to be one of the most commonly prescribed treatments for advanced pancreatic cancer [25] . Lastly, to reduce the uncertainty around the survival data currently available, future head-to-head clinical trials that directly evaluate the efficacy of the various regimens (particularly, GnP vs. FOLFIR-INOX) should be considered. Note. All outcomes are discounted at an annual rate of 5%. G, gemcitabine monotherapy; GCap, gemcitabine þ capecitabine; GCis, gemcitabine þ cisplatin; GE, gemcitabine þ erlotinib; GF, gemcitabine þ 5-fluorouracil; GnP, gemcitabine þ nab-paclitaxel; GOx, gemcitabine þ oxaliplatin; ICER, incremental cost-effectiveness ratio (cost per QALY gained); LY, life-year; QALYs, quality-adjusted life-years.
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